Overview

Intravitreal Bevacizumab for Non-Arteritic Anterior Ischemic Optic Neuropathy

Status:
Unknown status
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
Non-Arteritic Ischemic Optic Neuropathy (NAION) is a disease producing swelling of the optic nerve (the "cable" going from the eye to the brain) resulting in decreased vision. About 15% of patients will experience NAION in the second eye; many of these patients will be left legally blind. Currently, there is no treatment for NAION and for patients in whom the second eye becomes involved by the disease the outcome can be devastating. The investigators are conducting a study where the investigators will inject a medication into the involved eye of patients with NAION. This medication might decrease the swelling of the optic nerve and improve their vision in that eye.
Phase:
Phase 2
Details
Lead Sponsor:
Mount Sinai Hospital, Canada
Treatments:
Bevacizumab